Dr. Bogdana Schmidt

And I think this one points a really great point on what we mentioned earlier with the patients who refuse cisplatin. In this set of patients, there are just 60-something percent of patients that enrolled on this trial We're cisplatinum eligible, but refusing cisplatinum.

And I think this one points a really great point on what we mentioned earlier with the patients who refuse cisplatin. In this set of patients, there are just 60-something percent of patients that enrolled on this trial We're cisplatinum eligible, but refusing cisplatinum.

I think speaking to investigator excitement potentially and wanting to get patients on trial, but also speaking to the fact that patients don't want cisplatinum. They want something newer, better, hopefully less toxic. And now that we have these newer agents, newer devices, delivery mechanisms, I think this is interesting to figure out how are we going to incorporate that into the paradigm.

I think speaking to investigator excitement potentially and wanting to get patients on trial, but also speaking to the fact that patients don't want cisplatinum. They want something newer, better, hopefully less toxic. And now that we have these newer agents, newer devices, delivery mechanisms, I think this is interesting to figure out how are we going to incorporate that into the paradigm.

I think speaking to investigator excitement potentially and wanting to get patients on trial, but also speaking to the fact that patients don't want cisplatinum. They want something newer, better, hopefully less toxic. And now that we have these newer agents, newer devices, delivery mechanisms, I think this is interesting to figure out how are we going to incorporate that into the paradigm.

Yeah, so just to quickly introduce Sunrise for kind of the concept. So this was the muscle invasive patients who were chemo ineligible or refusing, who got TAR200 plus citrelumab versus citrelumab monotherapy. And this was in that five to three randomization that maybe we can talk about a little bit. Those patients then went on to get radical cystectomy.

Yeah, so just to quickly introduce Sunrise for kind of the concept. So this was the muscle invasive patients who were chemo ineligible or refusing, who got TAR200 plus citrelumab versus citrelumab monotherapy. And this was in that five to three randomization that maybe we can talk about a little bit. Those patients then went on to get radical cystectomy.

Yeah, so just to quickly introduce Sunrise for kind of the concept. So this was the muscle invasive patients who were chemo ineligible or refusing, who got TAR200 plus citrelumab versus citrelumab monotherapy. And this was in that five to three randomization that maybe we can talk about a little bit. Those patients then went on to get radical cystectomy.

And because this was phase two, we were looking at pathologic complete response patients. as the primary endpoint in these patients. And it was really, you know, I think, striking. CR in that combo arm, TAR200 plus citralumab, was 42%, which is sort of what we saw in the neoadjuvant chemo trials. Nothing went above 30%, right? So there's some neoadjuvant immunotherapy trials, but

And because this was phase two, we were looking at pathologic complete response patients. as the primary endpoint in these patients. And it was really, you know, I think, striking. CR in that combo arm, TAR200 plus citralumab, was 42%, which is sort of what we saw in the neoadjuvant chemo trials. Nothing went above 30%, right? So there's some neoadjuvant immunotherapy trials, but

And because this was phase two, we were looking at pathologic complete response patients. as the primary endpoint in these patients. And it was really, you know, I think, striking. CR in that combo arm, TAR200 plus citralumab, was 42%, which is sort of what we saw in the neoadjuvant chemo trials. Nothing went above 30%, right? So there's some neoadjuvant immunotherapy trials, but

PathCR 42% with complete response. I think it's promising, very promising.

PathCR 42% with complete response. I think it's promising, very promising.

PathCR 42% with complete response. I think it's promising, very promising.

Absolutely. And then just getting to Sunrise One, which was obviously in the non-muscle invasive space, they also showed incredibly promising results, 83% with just TAR 200 alone, which I think is really great. I'm personally, as a surgeon, a big believer in TAR. intravesical treatments for intravesical-only non-muscle invasive disease.

Absolutely. And then just getting to Sunrise One, which was obviously in the non-muscle invasive space, they also showed incredibly promising results, 83% with just TAR 200 alone, which I think is really great. I'm personally, as a surgeon, a big believer in TAR. intravesical treatments for intravesical-only non-muscle invasive disease.

Absolutely. And then just getting to Sunrise One, which was obviously in the non-muscle invasive space, they also showed incredibly promising results, 83% with just TAR 200 alone, which I think is really great. I'm personally, as a surgeon, a big believer in TAR. intravesical treatments for intravesical-only non-muscle invasive disease.

But looking at, there have been a couple combination trials now, right? So the Sunrise 1, looking initially with a citrelumab plus tar, and then you have data with creatostimogene in combination with PEMBRO. I think that, and then, of course, we had the PEMBRO data alone, which To me, that doesn't seem to be the primary direction that people are going.

But looking at, there have been a couple combination trials now, right? So the Sunrise 1, looking initially with a citrelumab plus tar, and then you have data with creatostimogene in combination with PEMBRO. I think that, and then, of course, we had the PEMBRO data alone, which To me, that doesn't seem to be the primary direction that people are going.

But looking at, there have been a couple combination trials now, right? So the Sunrise 1, looking initially with a citrelumab plus tar, and then you have data with creatostimogene in combination with PEMBRO. I think that, and then, of course, we had the PEMBRO data alone, which To me, that doesn't seem to be the primary direction that people are going.